Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Tetracosactide (Primary)
- Indications Post-dural puncture headache
- Focus Therapeutic Use
- Acronyms ESYBRECHE
- 11 Oct 2016 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.
- 11 Oct 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Nov 2018.
- 08 Jul 2016 New trial record